Previous 10 | Next 10 |
RAPIDe-3, a global Phase 3 clinical study of deucrictibant for the on-demand treatment of HAE, to initiate within 1H24 Results of nonclinical rodent toxicology study submitted to the FDA Jochen Knolle, Ph.D., to transition to strategic advisor to the CEO and Executive Committee Comp...
2023-12-14 18:34:06 ET Summary BioCryst Pharmaceuticals, Inc. proof-of-concept data from a phase 1 study, using BCX10013 for the treatment of patients with complement-mediated disorders, is expected in 2024. Oral C2, C5, and Bifunctional inhibitor drugs are also being advanced to ...
2023-12-11 15:41:33 ET Summary BioCryst faces heightened competition in the HAE market due to Pharvaris' positive CHAPTER-1 study of deucrictibant. Despite strong Q3 2023 revenues, BioCryst's long-term debts cast a shadow over its financial stability. The market reacted to Pha...
ZUG, Switzerland, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the presentation of one oral session and two posters at th...
2023-12-06 12:15:22 ET More on BioCryst, Pharvaris, etc. BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2023 Earnings Call Transcript BioCryst Pharmaceuticals: Q3 Earnings May Not Halt This Stock's Bear Run Pharvaris surges on mid-stage success for hereditary angioedema th...
2023-12-06 07:46:42 ET More on Pharvaris Seeking Alpha’s Quant Rating on Pharvaris Historical earnings data for Pharvaris Financial information for Pharvaris For further details see: Pharvaris surges on mid-stage success for hereditary angioedema t...
ZUG, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris”, Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, announced today the pricing of an underwritten...
Primary endpoint met; 40 mg/day orally administered deucrictibant significantly reduced mean monthly attack rate by 84.5% (p=0.0008) compared to placebo 92.3% reduction in occurrence of moderate and severe attacks 92.6% fewer attacks treated with on-demand medication by participants ...
ZUG, Switzerland, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of one abstract for oral presentation and t...
2023-11-15 08:10:00 ET More on Pharvaris Seeking Alpha’s Quant Rating on Pharvaris Historical earnings data for Pharvaris Financial information for Pharvaris For further details see: Pharvaris appoints Stefan Abele as Chief Technical Operations off...
News, Short Squeeze, Breakout and More Instantly...
Pharvaris N.V. Company Name:
PHVS Stock Symbol:
NASDAQ Market:
2024-06-13 23:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Deucrictibant substantially resolved symptoms of an HAE attack in 78.6% participants within 24 hours High treatment satisfaction of deucrictibant...
Deucrictibant substantially resolved symptoms of an HAE attack in 78.6% participants within 24 hours High treatment satisfaction of deucrictibant driven by favorable effectiveness subdomain score compared to placebo ZUG, Switzerland, June 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasd...